Abstract: Compositions comprising sun-care actives and self adapting polymers are disclosed. Self adapting polymers align themselves with the hydrophilic group pointing to the surface during application thus delivering an aesthetically pleasing surface to the consumers with a pleasant after feel. These polymers then rearrange upon contact with water so that the hydrophobic groups now point to the surface which then increases the water resistance of the formulation.

Abstract: A storage-stable solid composition comprising a tooth whitening effective amount of a particulated inorganic salt of peroxymonosulfate, and a particulated drying agent.

Abstract: Anhydrous antiperspirant stick or soft solid composition comprising an antiperspirant active system, thickening agent, and non-aqueous carrier oil, characterised in that the particulate antiperspirant active system comprises an aluminium sesequichlorohydrate of formula Al2(OH)4.4Cl1.6 to Al2(OH)4.9Cl1.1 activated with a water soluble calcium salt.

Abstract: Disclosed is a compound of the formula (I), (IIA) or (IIB) for use to treat hyperpigmentation of human skin by inhibiting the activity of human tyrosinase in an animate substrate which is human skin containing human tyrosinase. (I) (IIA) (IIB) where: X is oxygen, sulphur, selenium or tellurium; R is —OH, alkyl, aryl or peptide group: R1 is —OH, alkyl, aryl or peptide group; R2 is —OH, alkyl, aryl or peptide group; n is an integer from 2 to 5; m is an integer from 2 to 4 and p is an integer from 2 to 4.

Abstract: [Problem] An object of the invention is to provide a novel complex that can be used as an emulsifier. [Solving means] A complex in which an amide alcohol and a carboxyl group-containing polymer exerts an excellent emulsifying power for oil having a wide range of required HLB.

Abstract: A method for shaping keratin fibres comprising: providing a crosslinking composition, wherein the crosslinking composition comprises: an active agent, wherein the active agent comprises at least two functional groups selected from: —C(OH)— and —C(?O)OH; and wherein if the active agent has three or more —C(OH)— groups, then the active agent has 4 or more carbon atoms; and wherein no 1 carbon atom is functionalized with more than one functional group; and wherein the active agent has a molecular weight of 500 g/mol or less; a photocatalyst; a cosmetically acceptable carrier; and applying the crosslinking composition to keratin fibres, mechanically shaping the keratin fibres with an appliance or implement, and exposing the composition to electromagnetic radiation having a wavelength of from about 300 nm to about 750 nm. Also a related composition, use, kit and process.

Abstract: The purpose of the present invention is to provide an oil-in-water emulsion composition exhibiting high UV-protective capabilities with which it is possible to uniformly and stably disperse a hydrophobized metal oxide into an inner phase (oil phase) without detracting from the inherent fresh sensation on use of an oil-in-water emulsion composition even when a high amount of the hydrophobized metal oxide is compounded therewith. In summary, the present invention is an oil-in-water emulsion composition characterized by including (A) 0.1-5 mass % of polyether-modified silicone having an HLB (Si) of 5-14, (B) one or more hydrophilic thickeners, (C) a metal oxide hydrophobized by an agent other than metal soap, and (D) nonvolatile oil other than silicone oil, the (C) hydrophobized metal oxide being present in the inner phase.

Abstract: A sweetener composition comprising: at least one sweetener; at least one anti-foaming agent; and at least one flavour enhancer, wherein the flavour enhancer is: at least one high potency sweetener that contains hydrophilic and hydrophobic structural moieties; and used in an amount below its sweetness threshold.

Abstract: Methods for providing broad spectrum photo protection to skin using antioxidants that provide UVA protection to skin are described. The methods include topically applying a cosmetic composition comprising: (a) at least one antioxidant having an Oxygen Radical Absorbance Capacity (ORAC) of at least 10,000 ?mol TE/g and a Hydroxyl Radical Absorbance Capacity (HORAC) of at least 2,600 ?mol GAE/g; (b) at least one organic UV filter; and (c) a cosmetically acceptable carrier; wherein the cosmetic composition provides an increase in UVAPPD PF of at least 30% relative to an otherwise identical cosmetic composition without the antioxidant(s) of (a). The disclosure also relates to the cosmetic compositions useful in the described methods.

Abstract: Sex hormone-binding globulin and/or any fragment thereof for use as a medicament, in particular for use in the treatment of obesity and hepatic steatosis. The invention also relates to the cosmetic use of the sex hormone-binding globulin and/or any fragment thereof for improving the bodily appearance of a mammal with subcutaneous fat herniated or accumulated within the fibrous connective tissue under the skin, in particular the cosmetic use is for cellulite.

Abstract: Provided is a novel peptide and a cosmetic composition for inhibiting a skin-aging or a skin-wrinkle formation including the same. The peptide has activities for facilitating the bindings between keratinocytes; and increasing the expressions of junction proteins significantly.

Abstract: A composition comprising a cosmetically or pharmaceutically or therapeutically effective amount of a peptide comprising an amino acid sequence of SEQUENCE ID NO. 1. Modified peptides, and therapeutic and cosmetic uses of the peptide are also disclosed.

Abstract: The present disclosure relates to compositions suitable as leave-in hairstyling compositions comprising (a) a first polysaccharide comprising inulin; (b) a second polysaccharide comprising carrageenan; (c) a third polysaccharide; and (d) a humectant. The compositions as leave-on hair styling do not require synthetic film-forming polymers nor do they require silicones. The leave-on hair styling compositions are particularly useful in methods for imparting durable styling or shaping benefits to hair.

Abstract: The purpose of the present invention is to solve the problem, in powder hair dye compositions that contain a percarbonate, that a change occurs in the dyed color tone before and after storage when the composition contains metaaminophenol, 5-aminoorthocresol, resorcin, or a salt thereof, as an oxidation dye. To solve the aforementioned problem, a powder hair dye composition containing (A) a percarbonate, (B) a starch, and (C) an oxidation dye is provided, characterized in that the composition contains at least 7 mass % starch (B) and in that the oxidation dye (C) contains at least one selected from metaaminophenol, 5-aminoorthocresol, resorcin, and salts thereof. Thus, a powder hair dye composition can be obtained which suppresses change in the dye color tone before and after storage and which has excellent storage stability.

Abstract: The invention presents a fast-drying nail polish topcoat composition with high shine and long wear. The disclosed combination of at least two cellulose-derived primary film formers, a ketone-aldehyde resin, a plasticizer, a hydrocarbon oil, and solvents selected such that no more than 20% of the solvents have an evaporation rate less than or equal to butyl acetate provides a nail polish that can be dried within 30 seconds on fingernails without sacrificing other critical properties.

Abstract: Provided is an aqueous gelling agent composition, including: compound (A) represented by the general formula (1); and compound (B) represented by the general formula (2), wherein a mass ratio of compound (A) to compound (B), (A): (B), is from 95:5 to 85:15: where R1, R2, R8, R9, R10, R11, R15, and R16 each independently represent a hydrocarbon group having 4 to 20 carbon atoms, R3, R5, R7, R12, and R14 each independently represent a divalent hydrocarbon group having 2 to 4 carbon atoms, R4, R6, and R13 each independently represent a divalent hydrocarbon group having 3 to 16 carbon atoms, a, e, j, and m each independently represent a number of 10 to 100, d represents a number of 100 to 500, and g represents a number of 1 to 10.

Abstract: The present invention relates to an inorganic material comprising particles of three-dimensional ordered macroporous structure comprising spherical pores, said pores having an average pore diameter ranging from 50 nm to 10 ?m, the pore diameter varying by no greater than 20%, the surface of said pores being coated by an absorber agent of the visible wavelength spectrum, said particles having an average largest dimension ranging from 1 to 50 ?m, and wherein said particles are coated with at least a hydrophobic component. The invention further relates to a process for preparing said inorganic material.

Abstract: A nail care system containing (1) at least one composition containing at least one adhesive agent, at least one primary film former and at least one plasticizer; and (2) an applicator is provided.

Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.

Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HC1 given every 6 hours.

Abstract: A method of treating pain, e.g., acute post-operative pain, by intravenously administering to a human patient(s) a dose of tramadol of about 45 mg to about 80 mg, based on tramadol hydrochloride, together with an intravenous dose of a therapeutically effective amount of ketorolac about every 6 hours.

Abstract: Described herein are methods for reducing the risks of exposure to air pollutants, comprising nasally administering to a subject in need thereof a composition that counteracts the effects of one or more air pollutants, wherein the composition is adapted for nasal administration. In some embodiments the composition comprises an agent that binds to one or more air pollutants, wherein the agent comprises one or both of nonporous silicon dioxide and porous silicon dioxide and/or the composition provides a physical barrier between one or more air pollutants and internal nasal surfaces. Also described are nasal compositions comprising an agent comprising one or both of nonporous silicon dioxide and porous silicon dioxide, a lipophilic or partly lipophilic vehicle, and a surfactant, wherein the composition is adapted for nasal administration. The compositions also may comprise other agents, such as an immunosuppressant. Also described are methods of making and using the compositions.

Abstract: The present invention concerns a method for making an inhaled pharmaceutical composition with improved powder handling properties comprising a stearate, a method of preparing such a composition, and the use of such a stearate in a composition when dispensed into a receptacle for use in a dry powder inhaler receptacle.

Abstract: An active mesh nebulizer is used to generate a distribution of liquid particles or droplets having a diameter ranging from about 0.5 to about 5 micrometers (?m). Delivery and ingestion, by inhalation, of ethyl alcohol solution particles leads to rapid uptake of the alcohol solution by brain tissue, and avoids damage to the liver, gastrointestinal tract, and/or peripheral nervous system consistent with drinking ethyl alcohol. A brain effect of ethyl alcohol absorbed through alveoli in the lung occurs within less than 60 seconds, and body effects of alcohol consumption are reduced or eliminated. Delivery of ethyl alcohol to a user by absorption through alveoli provides a user with a brain effect while allowing tissue damage from drinking alcohol to heal. A lock out barcoded capsule containing ethyl alcohol, tethered to a smartphone application, prevents unauthorized use by non-designated users, or abuse by a designated user.

Abstract: A cosmetic or dermatological composition in the form of an oil-in-water nanoemulsion, including: a lipophilic phase (a) including at least one hydrocarbonated oil comprising at least one isoparaffin, and at least one cycloalkane, an emulsifying system (b) including at least one non-ionic emulsifier, and an aqueous phase (c), where the ratio between the lipophilic phase (a) and the emulsifying system (b) is higher than, or equal to, 0.5 in terms of weight.

Abstract: A method of preparing a wound model. The method includes simulating a non-healing wound edge, simulating eschar, simulating a fibrin layer, simulating biofilm, and simulating foreign debris.

Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.

Abstract: A multi-component nanoconstruct for use in diagnostic and therapeutic applications includes at least three nanoparticles linked together to form the nanochain. The nanoparticles are linked to form the nanochain by linking first linkers and/or second linkers disposed on separate nanoparticles.

Abstract: The present invention relates to an immediate release formulation of pharmaceutical compounds.

Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

Abstract: The present invention relates to rapidly disintegrating oral dosage forms, more particularly to rapidly disintegrating tablets containing (1S,2S,3R,5S)-3-[7-{[1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5 5-(2-hydroxyethoxy)cyclopentane-1,2-diol and a disintegrating excipient. Blister packs suitable for use with the rapidly disintegrating oral dosage form are also disclosed.

Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.

Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.

Abstract: The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N, wherein the formulation mixture is combined with a solvent for the polymer (C) at least in quantities such that the formulation mixture is at least uniformly moistened, the at least moistened composition is optionally divided into sub-portions, dried and shaped to yield the dosage form.

Abstract: Provided herein are methods of inhibiting proliferation of one or more tumor cells comprising contacting the one or more tumor cells with a composition comprising one or more epigenetic drugs that inhibit one or more epigenetic mechanisms of the tumor cells, wherein the one or more epigenetic drugs are encapsulated in a nanogel. The invention is also directed to methods of treating a tumor, metastasis of a tumor or a combination thereof in an individual in need thereof. The invention is also directed to a method of sequentially delivering one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell and one or more chemotherapeutic drugs to an individual that has a tumor. Compositions which comprise one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell, wherein the one or more epigenetic drugs are encapsulated in a nanogel.

Abstract: The invention relates to a process for the preparation of a product comprising one or more nanoparticles of calcium phosphate (CaP-NP) with negative surface charge having a ?-potential in the range from ?41.0 mV to ?27.0 mV comprising the steps of: a) maintaining a mixture having a pH in the range from 7 to 10 and comprising an aqueous solution of calcium, an aqueous solution of phosphate and a solution of citrate ions at a temperature in the range from 20° C. to 40° C. for a time in the range from 30 seconds to 10 minutes; b) removing non-reacted ions from the solution of step a), thus obtaining a suspension of one or more nanoparticles of calcium phosphate (CaP-NP); c) recovering the product of one or more nanoparticles of calcium phosphate (CaP-NP) from the suspension of step b). In an advantageous embodiment, the process of the invention provides, in the mixture of step a), also an aqueous solution of one or more therapeutic/diagnostic compounds.

Abstract: A particle comprising a first fraction containing an active ingredient and a second fraction containing a surfactant, and having a number average particle diameter of from 1 to 100 nm.

Abstract: The present invention relates to a product for at least one of medicinal, cosmetic, coloring or dermatologic use. The product comprises a fibrous plant product and a plant extract which is applied thereto. Further, the invention relates to a corresponding method for producing said product and its use in at least one of medicinal, cosmetic, coloring or dermatologic products or applications or treatments. The plants used may be all plants comprising one or more substances of interest to achieve a desired medicinal, cosmetic, coloring or dermatologic effect.

Abstract: The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.

Abstract: The invention provides compounds, compositions, methods, and kits for the treatment of neurogenic inflammation.

Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC).

Abstract: The present disclosure provides a pharmaceutical preparation of a compound of formula (I) or a stereoisomer, pharmaceutically acceptable salt, or prodrug thereof. The present disclosure further provides a method for general anesthesia or sedation for mammals. Also provided are kits and manufactured products of the medicament and the pharmaceutical composition and a method for using the medicament and the pharmaceutical composition.

Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.

Abstract: Disclosed herein are methods for (a) treating, inhibiting, or reducing aging of a subject, (b) treating, inhibiting, or reducing an age-related symptom or an age-related disease in a subject, and/or (c) increasing the lifespan of a subject which comprise administering to the subject one or more ketobutyrate compounds and compositions thereof.

Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with phenyl butyric acid (PBA) or a pharmaceutically acceptable salt thereof and an anti-cancer composition.

Abstract: Compounds of Formula (I), and pharmaceutically effective salts thereof; wherein R1-R14, m, n, o, p, q and r are as defined herein, are provided for treatment of for increasing insulin sensitivity, reducing insulin resistance, preventing insulin resistance and treating insulin resistance disorders.

Abstract: The invention provides complexes of Zn2+ of formulae (la) and (IIa) that are useful for treating cancer, as well as compositions and kits comprising such complexes.

Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.